Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles

Biomaterials

Volumn 33, Issue 21, 2012, Pages 5414-5422

  Zhang, Fan ^a   Huang, Xinglu ^b   Zhu, Lei ^b,c   Guo, Ning ^c   Niu, Gang ^b   Swierczewska, Magdalena ^b   Lee, Seulki ^b   Xu, Hong ^d   Wang, Andrew Y ^d   Mohamedali, Khalid A ^e   Rosenblum, Michael G ^e   Lu, Guangming ^a   Chen, Xiaoyuan ^b,c  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c XIAMEN UNIVERSITY   (China)

^d OCEAN NANOTECH LLC   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Iron oxide nanoparticles (IONPs); Magnetic resonance imaging (MRI); RGD peptides; Therapy response; Tumor targeting

Indexed keywords

AMPHIPHILIC TRIBLOCK COPOLYMERS; ANTICANCER DRUG; CELLULAR UPTAKE; CLINICAL TRANSLATION; CONTRAST AGENT; CROSSLINKED; GLIOBLASTOMAS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; IN-VITRO; INTEGRINS; IRON OXIDE NANOPARTICLE; NON-INVASIVE IMAGING; NON-INVASIVE MONITORING; ORTHOTOPIC; PRECLINICAL STUDIES; RGD PEPTIDE; THERAPY RESPONSE; TUMOR RESPONSE; TUMOR SIZE; TUMOR TARGETING; VASCULAR DISRUPTING AGENTS;

BLOCK COPOLYMERS; ENDOTHELIAL CELLS; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES; PEPTIDES;

TUMORS;

ARGINYLGLYCYLASPARTIC ACID; COPOLYMER; GELONIN; IRON OXIDE NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CELL TRANSPORT; CONTROLLED STUDY; CROSS LINKING; DISEASE SEVERITY; DRUG CONJUGATION; DRUG TARGETING; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIGENS, CD31; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FERRIC COMPOUNDS; GLIOBLASTOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRIN BETA3; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; STAINING AND LABELING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860914859     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.04.032     Document Type: Article

References (35)

1. Weber W.A. Assessing tumor response to therapy. J Nucl Med 2009, 1(50 Suppl):1S-10S.
2. Husband J.E., Schwartz L.H., Spencer J., Ollivier L., King D.M., Johnson R., et al. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004, 90(12):2256-2260.
3. Han Z., Fu A., Wang H., Diaz R., Geng L., Onishko H., et al. Noninvasive assessment of cancer response to therapy. Nat Med 2008, 14(3):343-349.
4. Day S.E., Kettunen M.I., Gallagher F.A., Hu D.E., Lerche M., Wolber J., et al. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 2007, 13(11):1382-1387.
5. de Langen A.J., van den Boogaart V., Lubberink M., Backes W.H., Marcus J.T., van Tinteren H., et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med 2011, 52(1):48-55.
6. Lee N., Hyeon T. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. Chem Soc Rev 2012, 41(7):2575-2589.
7. Huang J., Zhong X., Wang L., Yang L., Mao H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics 2012, 2(1):86-102.
8. Zhen Z., Xie J. Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging. Theranostics 2012, 2(1):45-54.
9. Huang X., Zhuang J., Chen D., Liu H., Tang F., Yan X., et al. General strategy for designing functionalized magnetic microspheres for different bioapplications. Langmuir 2009, 25(19):11657-11663.
10. Gajbhiye V., Jain N.K. The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 2011, 32(26):6213-6225.
11. Tzeng S.Y., Guerrero-Cazares H., Martinez E.E., Sunshine J.C., Quinones-Hinojosa A., Green J.J. Non-viral gene delivery nanoparticles based on poly(β-amino esters) for treatment of glioblastoma. Biomaterials 2011, 32(23):5402-5410.
12. Veiseh O., Sun C., Fang C., Bhattarai N., Gunn J., Kievit F., et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 2009, 69(15):6200-6207.
13. Dilnawaz F., Singh A., Mewar S., Sharma U., Jagannathan N.R., Sahoo S.K. The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials 2012, 33(10):2936-2951.
14. 121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 2002, 99(12):7866-7871.
15. 121/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 2005, 7(5):486-496.
16. 121/rGel. J Nucl Med 2007, 48(3):445-454.
17. 121 fusion proteins in Escherichia coli. J Biotechnol 2007, 128(3):638-647.
18. Rosen B.R., Belliveau J.W., Vevea J.M., Brady T.J. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990, 14(2):249-265.
19. Chen K., Xie J., Xu H., Behera D., Michalski M.H., Biswal S., et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials 2009, 30(36):6912-6919.
20. Park J., An K., Hwang Y., Park J.G., Noh H.J., Kim J.Y., et al. Ultra-large-scale syntheses of monodisperse nanocrystals. Nat Mater 2004, 3(12):891-895.
21. Yu W.W., Falkner J.C., Yavuz C.T., Colvin V.L. Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem Commun (Camb) 2004, (20):2306-2307.
22. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17(11):1359-1370.
23. Kiessling F., Huppert J., Zhang C., Jayapaul J., Zwick S., Woenne E.C., et al. RGD-labeled USPIO inhibits adhesion and endocytotic activity of αvβ3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology 2009, 253(2):462-469.
24. Schnell O., Krebs B., Carlsen J., Miederer I., Goetz C., Goldbrunner R.H., et al. Imaging of integrin αvβ3 expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol 2009, 11(6):861-870.
25. Cruet-Hennequart S., Maubant S., Luis J., Gauduchon P., Staedel C., Dedhar S. αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 2003, 22(11):1688-1702.
26. Yang C., Hayashida T., Forster N., Li C., Shen D., Maheswaran S., et al. The integrin αvβ3/5 ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers. Cancer Res 2011, 71(3):937-945.
27. Ye Y., Chen X. Integrin targeting for tumor optical imaging. Theranostics 2011, 1:102-126.
28. Zhou Y., Chakraborty S., Liu S. Radiolabeled Cyclic RGD peptides as radiotracers for imaging tumors and Thrombosis by SPECT. Theranostics 2011, 1:58-82.
29. Hsu A.R., Hou L.C., Veeravagu A., Greve J.M., Vogel H., Tse V., et al. In vivo near-infrared fluorescence imaging of integrin αvβ3 in an orthotopic glioblastoma model. Mol Imaging Biol 2006, 8(6):315-323.
30. Chen X., Conti P.S., Moats R.A. In vivo near-infrared fluorescence imaging of integrin αvβ3 in brain tumor xenografts. Cancer Res 2004, 64(21):8009-8014.
31. Gianella A., Jarzyna P.A., Mani V., Ramachandran S., Calcagno C., Tang J., et al. Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano 2011, 5(6):4422-4433.
32. Zhang C., Jugold M., Woenne E.C., Lammers T., Morgenstern B., Mueller M.M., et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 2007, 67(4):1555-1562.
33. Li J., Zhang C., Yang K., Liu P., Xu L.X. SPIO-RGD nanoparticles as a molecular targeting probe for imaging tumor angiogenesis using synchrotron radiation. J Synchrotron Radiat 2011, 18(Pt 4):612-616.
34. Sarin H., Kanevsky A.S., Wu H., Brimacombe K.R., Fung S.H., Sousa A.A., et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008, 6:80.
35. Yang M., Gao H., Sun X., Yan Y., Quan Q., Zhang W., et al. Multiplexed PET probes for imaging breast cancer early response to VEGF/rGel treatment. Mol Pharm 2011, 8(2):621-628.